Login to Your Account

Clinic Roundup

Tuesday, April 30, 2013
• Neuralstem Inc., of Rockville, Md., reported that final data on the intraspinal delivery method employed in its NSI-566 Phase I trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were presented at the American Association of Neurological Surgeons Annual Meeting.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription